Analysing stratified medicine business models and value systems: Innovation-regulation interactions

New Biotechnology

Volumn 29, Issue 6, 2012, Pages 709-719

  Mittra, James ^a   Tait, Joyce ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUSINESS MODELS; CO-DEVELOPMENT; CONVERGENCE MODEL; DRUG DEVELOPMENT; HEALTH CARE PROVIDERS; INNOVATION SYSTEM; LIFE-SCIENCES; POLICY INITIATIVES; REGULATORY INTERACTIONS; REGULATORY REQUIREMENTS; VALUE CHAINS; VALUE CREATION PROCESS; VALUE SYSTEMS;

COORDINATION REACTIONS; DRUG THERAPY; HEALTH CARE; SUSTAINABLE DEVELOPMENT;

INNOVATION;

BIOLOGICAL MARKER;

ARTICLE; COMMERCIAL PHENOMENA; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HUMAN; MEDICINE; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REIMBURSEMENT; STANDARD;

COMMERCE; COOPERATIVE BEHAVIOR; DRUG DISCOVERY; HUMANS; MODELS, ECONOMIC; SOCIAL CONTROL, FORMAL; THERAPIES, INVESTIGATIONAL;

EID: 84865437117     PISSN: 18716784     EISSN: 18764347     Source Type: Journal    
DOI: 10.1016/j.nbt.2012.03.003     Document Type: Article

References (52)

1. Mittra J. Impact of the life sciences on organisation and management of R&D in large pharmaceutical firms. Int. J. Biotechnol. 2008, 10:416-440.
2. Mittra J., et al. From maturity to value-added innovation: lessons from the pharmaceutical and agro-biotechnology industries. Trends Biotechnol. 2011, 29:105-109.
3. Tait J., et al. The life science industry sector: evolution of agro-biotechnology in Europe. Sci. Public Policy 2002, 29:253-258.
4. Tait J., et al. Health Biotechnology to 2030. Report to OECD International Futures Project, The Bio-Economy to 2030: Designing a Policy Agenda 2008, OECD, Paris, 51 pp. http://www.oecd.org/dataoecd/12/10/40922867.pdf.
5. Drews J., Ryser S. Innovation deficit in the pharmaceutical industry. Drug Information J. 1996, 30:97-108.
6. Schmid E.F., Smith A. Is declining innovation in the pharmaceutical industry a myth?. Drug Discov. Today 2005, 10:1031-1038.
7. Mittra J. Life science innovation and the restructuring of the pharmaceutical industry: merger, acquisition and strategic alliance behaviour large firms. Technol. Anal. Strat. Manage. 2007, 19:279-301.
8. Horrobin D.F. Realism in drug discovery - could Cassandra be right?. Nat. Biotechnol. 2001, 19:1099-1100.
9. Fernandez L. Splashes and ripples: the chemical industry in the new millennium. Chem. Ind. 1985, 23:787-789.
10. Tait J., Mittra J. Industry challenges. Chem. Ind. 2004, 23:24.
11. Kraft, A. (2004) Genomics as an emergent industry: panacea for pharmaceutical innovation? Paper presented at Business and Society Conference, June 2004, Association of British Historians, Nottingham.
12. Hughes B. 2009 FDA drug approvals. Nat. Rev. Drug Discov. 2010, 9:89-92.
13. Huckman R., Strick E. GlaxoSmithKline: reorganizing drug discovery (A). Harv. Bus. School Case Study 2005, 9-605-074.
14. Ledford H. Drug buddies. Nature 2011, 474:433-434.
15. Chataway J., et al. The International AIDS Vaccine Initiative (IAVI) in a changing landscape of vaccine development: a public private partnership as knowledge broker and integrator. Eur. J. Dev. Res. 2007, 19:100-117.
16. Hanlin R., et al. Global health public-private partnerships: IAVI, partnerships and capacity building. Afr. J. Med. Med. Sci. 2007, 36:69-75.
17. Cockburn I.M. The changing structure of the pharmaceutical industry. Health Affairs 2004, 23:10-22.
18. Schulman K.A., et al. Personalized medicine and disruptive innovation: implications for technology assessment. Genet. Med. 2009, 11:577-581.
19. Mittra, J., and Milne, C.P. (eds). (2012). Translational Medicine: The Future of Therapy, Pan Stanford Publishing, forthcoming.
20. Pammolli F., et al. The productivity crisis in pharmaceutical R&D. Nat. Rev. Drug Discov. 2011, 19:428-438.
21. Pardridge W.M. Translational science: what is it and why is it so important?. Drug Discov. Today 2003, 18:813-815.
22. Horig H., Pullman W. From Bench to Clinic and Back: Perspective on the First 1st IQPC Translational Research Conference. J. Transl. Med. 2004, 2:44.
23. Dimasi J.A., Grabowski H.G. The cost of biopharmaceutical R&D: is biotech different?. Manage. Decis. Econ. 2007, 28:469-479.
24. Kaitin K.I. Deconstructing the drug development process: the new face of innovation. Clin. Pharmacol. Therapeut. 2010, 87:356-361.
25. TSB Stratified Medicine in the UK: Vision and Roadmap 2011, Technology Strategy Board, http://www.arthritisresearchuk.org/PDF/Roadmap_StratifiedMedInTheUK%20_final.pdf.
26. AMS Optimizing Stratified Medicine R&D: Addressing Scientific and Economic Issues. Report of a Meeting Organised by the Academy of Medical Sciences 2007, December, Roche and GE Healthcare, Academy of Medical Sciences, London.
27. Trusheim M.R., et al. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug Discov. 2007, 6:287-293.
28. Ferrara J. Personalized medicine: challenging pharmaceutical and diagnostic company business models. McGill J. Med. 2007, 10:59-61.
29. Tait J. Systemic interactions in life science innovation. Technol. Anal. Strat. Manage. 2007, 19:257-277.
30. Hedgecoe A., Martin P. The drugs don't work: expectations and the shaping of pharmacogenetics. Soc. Stud. Sci. 2003, 33:327-364.
31. Hedgecoe A. Context, ethics and pharmacogenetics. Stud. History Philos. Biol. Biomed. Sci. 2006, 37:566-582.
32. Martin P., Morrison M. Realising the Potential of Genomic Medicine 2006, July, Report Published by the Royal Pharmaceutical Society of Great Britain, http://www.bioscienceresource.org/docs/GeneticMedicine.pdf.
33. Smart A., et al. Tailored medicine: whom will it fit? The ethics of patient and disease stratification. Bioethics 2004, 18:322-343.
34. Lowrie H., et al. Interdisciplinary Methodology for the Analysis of Life Science Innovation Systems 2011, Innogen Working Paper 92. http://www.genomicsnetwork.ac.uk/media/Innogen%20Working%20Paper%2092.pdf.
35. Wamae W., et al. Translational Research in Agriculture and Food Production. RAND Technical Report to BBSRC and DEFRA 2011, RAND Europe, Cambridge, UK.
36. Phillips K.A., et al. Diagnostics and biomarker development: priming the pipeline. Nat. Rev. Drug Discov. 2006, 5:463-469.
37. Davis J.C., et al. The microeconomics of personalized medicine: today's challenge and tomorrow's promise. Nat. Rev. Drug Discov. 2009, 8:279-286.
38. Hughes B. Developing tools for stratified medicine. Nat. Rev. Drug Discov. 2009, 8:919-920.
39. TSB Stratified medicine: pathways to partnership in therapeutic-diagnostic development. Output Document of Technology Strategy Board Business Focused Workshop 2010.
40. Trusheim M.R., et al. Quantifying factors for the success of stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug Discov. 2011, 10:817-833.
41. Paul S.M., et al. How to improve R&D productivity; the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 2010, 9:203-214.
42. Naylor S., Cole T. Companion diagnostics in the pharmaceutical industry. Part 11: Business models. Drug Discov. World 2010, Summer:61-68.
43. Woodcock J., Woosley R. The FDA critical path initiative and its influence on new drug development. Annu. Rev. Med. 2008, 59:1-12.
44. FDA Critical Path Opportunities Report 2006, March, US Department of Health and Human Services.
45. FDA Advancing Regulatory Science at FDA: A Strategic Plan 2011, August, www.fda.gov/regulatoryscience.
46. Milne C.P., Tait J. Evolution along the Government-Governance Continuum: FDA's orphan products and fast track programs as exemplars of 'what works' for innovation and regulation. Food Drug Law J. 2009, 64:733-753.
47. Cooksey D. A Review of UK Health Research Funding 2006, www.hm-treasury.gov.uk/independent_reviews/cooksey_review/cookseyreview_index.cfm.
48. Tait J., et al. Appropriate Governance of the Life Sciences - 2: The Case for Smart Regulation 2008, Innogen Policy Brief, http://www.genomicsnetwork.ac.uk/innogen/publications/innogenpolicybriefs/title,25375,en.html.
49. Blair E.D., et al. Sustaining development of stratified medicines in the UK healthcare system: a commentary. Personal. Med. 2011, 8:517-521.
50. Meckley L.M., Neumann P.J. Personalized medicine: factors influencing reimbursement. Health Policy 2010, 94:91-100.
51. Aspinall M.G., Hamermesh R.G. Realizing the promise of personalized medicine. Harv. Bus. Rev. 2007, October.
52. Chataway J., et al. The governance of agro- and pharmaceutical biotechnology innovation: public policy and industrial strategy. Technol. Anal. Strat. Manage. 2006, 18:1-17.